BIOCRYST PHARMACEUTICALS INC (BCRX) FY2025 10-K Annual Report
BIOCRYST PHARMACEUTICALS INC (BCRX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
BIOCRYST PHARMACEUTICALS INC FY2025 10-K Analysis
Business Overview
- • Core business model: Biopharmaceutical company focused on development and commercialization of pharmaceutical products, including rare disease treatments like ORLADEYO
- • Strategic shift: Sale of European ORLADEYO business with a Global Brand and Support Agreement limiting sole control over European brand positioning
- • Quantitative metric: 52-week stock price range $6.00 to $11.31 per share for fiscal year 2025
- • Noteworthy risk factor: Increased reliance on AI and cybersecurity amid expanded employee base and remote work, introducing new regulatory and operational risks
Management Discussion & Analysis
- • No revenue or YoY change figures provided in the MD&A section
- • No specific profitability or margin % data disclosed
- • No segment performance numbers or ranking included
- • Merger-related expenses expected to be substantial but no $ amounts given
- • Key risks: economic instability affecting counterparties, Merger integration challenges, clinical trial uncertainties, regulatory approval delays, and rare disease market complexities impacting future results and capital needs
Risk Factors
- • FDA approval of ORLADEYO oral pellet for pediatric HAE patients aged 2 to <12 years in December 2025
- • Revenues from European ORLADEYO business divested in October 2025 for $254.5M cash proceeds
- • Operational dependency risk from divestiture of BioCryst Ireland holding European ORLADEYO assets and employees
- • Competitive risk from ongoing clinical development of Navenibart showing sustained HAE attack suppression in long-term trial
- • Potential revenue milestone up to $14.0M from Neopharmed Gentili contingent on European sales before December 2032
BIOCRYST PHARMACEUTICALS INC FY2025 Key Financial MetricsXBRL
Revenue
$875M
▲ +94.1% YoY
Net Income
$264M
▲ +396.9% YoY
Operating Margin
39.0%
▲ +3954bp YoY
Net Margin
30.2%
▲ +4988bp YoY
ROE
-221.4%
▼ -24012bp YoY
Total Assets
$514M
▲ +4.8% YoY
EPS (Diluted)
$1.21
▲ +381.4% YoY
Operating Cash Flow
$347M
▲ +767.8% YoY
Source: XBRL data from BIOCRYST PHARMACEUTICALS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on BIOCRYST PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.